INDIVIDUAL ARTICLE: Tildrakizumab for Real-World Psoriasis Care: Clinical Lessons From Medically Complex and Underserved Patient Populations.
Julian A Cortes, Boni Elewski, Sam Awan et al.
✦ AI-curated · Sources linked
Case in brief
This case review discusses 16 patients with moderate-to-severe plaque psoriasis treated with tildrakizumab, a monoclonal antibody targeting interleukin-23. Patients included older adults and those with complex comorbidities. Significant improvement in psoriasis was noted, particularly in high-impact areas, with durable disease control achieved without treatment-limiting adverse events. The treatment's practical administration schedule also addressed various patient access challenges.
Diagnostic / clinical pearl
Clinicians should consider tildrakizumab as a viable treatment option for patients with complex medical histories and comorbidities, as it has shown substantial efficacy and safety in real-world settings.
Why it matters
This case highlights the importance of integrating effective treatments like tildrakizumab into individualized care plans for patients with psoriasis, particularly those facing barriers to treatment.